Albert K Amegadzie

6362181, Mar 26, 2002

Aug 11, 2000

09/637949

Albert Kudzoi Amegadzie - Carrboro NC
Maureen Elizabeth Carey - Canton MI
John Michael Domagala - Canton MI
Liren Huang - Edmonton, CA
Ronald George Micetich - Sherwood Park, CA
Joseph Peter Sanchez - Novi MI
Rajeshwar Singh - Edmonton, CA
Michael Andrew Stier - Ypsilanti MI
Arkadii Vaisburg - Edmonton, CA

Warner-Lambert Company - Morris Plains NJ

A61K 31535

5142355, 514290, 546 98, 546 99, 544 96

Benzo[de]isoquinoline-1,3-diones which are selective inhibitors of bacterial DNA gyrase and DNA topoisomerase useful in antibacterial agents are described as well as methods for their preparation and formulation. Novel intermediates useful in the preparation of the final products are also described.

7179804, Feb 20, 2007

Apr 22, 2003

10/512248

Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
Erik James Hembre - Indianapolis IN, US
Jian Eric Hong - Carmel IN, US
Louis Nickolaus Jungheim - Indianapolis IN, US
Michael Alan Robertson - Indianapolis IN, US
Kenneth Allen Savin - Indianapolis IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/4192
A61K 31/4406
A61K 31/4409
A61K 31/497
A61K 31/541
A61K 31/5377
C07D 261/08
C07D 413/06
C07D 417/14
C07F 7/10

5142278, 5142315, 51425505, 514340, 514359, 544 60, 544140, 544229, 546 14, 5462721, 548248, 548255

The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

7276516, Oct 2, 2007

Dec 13, 2004

10/596495

Jennifer Rebecca Allen - Indianapolis IN, US
Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
George Stuart Gregory - Fishers IN, US
Steven Andrew Hitchcock - Westlake Village CA, US
Paul J. Hoogestraat - Indianapolis IN, US
Daryl Lynn Smith - Fishers IN, US

Eli Lilly and Company - Indianapolis IN

A01N 43/42
A01N 43/38
A61K 31/44
C07D 471/02
C07D 491/02

514300, 514414, 514418, 514404, 546113, 5462771, 548469, 5483611

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e. g. , multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

7320994, Jan 22, 2008

Apr 22, 2003

10/512249

Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
Erik James Hembre - Indianapolis IN, US
Jian Eric Hong - Carmel IN, US
Louis Nickolaus Jungheim - Indianapolis IN, US
Brian Stephen Muehl - Greenwood IN, US
David Michael Remick - Fishers IN, US
Michael Alan Robertson - Indianapolis IN, US
Kenneth Allen Savin - Indianapolis IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/41
C07D 249/04

514359, 548255

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C-Calkane-diyl; Ris phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C-Calkyl, C-Calkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; Ris a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH).

7538114, May 26, 2009

Jun 26, 2007

11/823027

Stephen Hitchcock - Westlake Village CA, US
Albert Amegadzie - Moorpark CA, US
Wenyuan Qian - Camarillo CA, US
Xiaoyang Xia - Thousand Oaks CA, US
Scott S. Harried - Woodland Hills CA, US

Amgen Inc. - Thousand Oaks CA

A61K 31/4965
A01N 43/62
A61K 31/55
A01N 43/00
A61K 31/33
C07D 243/08
C07D 245/00
C07D 241/04
C07D 295/00

51425504, 514183, 514218, 540575, 540470, 544396, 544384

The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

7595339, Sep 29, 2009

Aug 17, 2007

11/840417

Jennifer Rebecca Allen - Indianapolis IN, US
Albert Kudzovi Amegadzie - Indianapolis IN, US
Kevin Matthew Gardinier - Indianapolis IN, US
George Stuart Gregory - Fishers IN, US
Stephen Andrew Hitchcock - Westlake Village CA, US
Paul J. Hoogestraat - Indianapolis IN, US
Daryl Lynn Smith - Fishers IN, US

Eli Lilly and Company - Indianapolis IN

A61K 31/40

514418

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e. g. , multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

7902356, Mar 8, 2011

Dec 16, 2005

11/721079

Albert Kudzovi Amegadzie - Indianapolis IN, US
James Peter Beck - Zionsville IN, US
Kevin Matthew Gardinier - Fishers IN, US
Erik James Hembre - Indianapolis IN, US
James Craig Ruble - Greenwood IN, US
Kenneth Allen Savin - Indianapolis IN, US
Brian David Wakefield - Skokie IL, US

Eli Lilly and Company - Indianapolis IN

C07D 265/36
C07D 413/00
C07D 401/00
C07D 513/02

544105, 544128, 544362, 546114

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R, q, p, R, t, Ar, L, Rand Rare as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

8101764, Jan 24, 2012

Jun 8, 2007

12/296557

Albert Kudzovi Amegadzie - Moorpark CA, US
Yen Dao - Indianapolis IN, US
Kevin Matthew Gardinier - Fishers IN, US
David Joseph Garmene - Indianapolis IN, US
Steven James Green - Indianapolis IN, US
Erik James Hembre - Indianapolis IN, US
Jianliang Lu - Fishers IN, US
Patrick Gianpietro Spinazze - Fishers IN, US

Eli Lilly and Company - Indianapolis IN

C07D 513/02

546114

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R, R, R, R, L, R, Rand Rare as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.